Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use

Zoltán Papp, Piergiuseppe Agostoni, Julian Alvarez, Dominique Bettex, Stefan Bouchez, Dulce Brito, Vladimir Černý, Josep Comin-Colet, Marisa G. Crespo-Leiro, Juan F. Delgado, Istvan Édes, Alexander A. Eremenko, Dimitrios Farmakis, Francesco Fedele, Cândida Fonseca, Sonja Fruhwald, Massimo Girardis, Fabio Guarracino, Veli Pekka Harjola, Matthias HeringlakeAntoine Herpain, Leo M.A. Heunks, Tryggve Husebye, Višnja Ivancan, Kristjan Karason, Sundeep Kaul, Matti Kivikko, Janek Kubica, Josep Masip, Simon Matskeplishvili, Alexandre Mebazaa, Markku S. Nieminen, Fabrizio Oliva, Julius Gyula Papp, John Parissis, Alexander Parkhomenko, Pentti Põder, Gerhard Pölzl, Alexander Reinecke, Sven Erik Ricksten, Hynek Riha, Alain Rudiger, Toni Sarapohja, Robert H.G. Schwinger, Wolfgang Toller, Luigi Tritapepe, Carsten Tschöpe, Gerhard Wikström, Dirk von Lewinski, Bojan Vrtovec, Piero Pollesello

Research output: Contribution to journalArticlepeer-review

45 Citations (Scopus)
Original languageEnglish
Article numbere19
JournalCardiac Failure Review
Volume6
DOIs
Publication statusPublished - 2020
Externally publishedYes

ASJC Scopus Subject Areas

  • Cardiology and Cardiovascular Medicine

Keywords

  • Acute heart failure
  • advanced heart failure
  • haemodynamics
  • inodilator
  • inotrope
  • neurohormone
  • regulatory clinical trial

Fingerprint

Dive into the research topics of 'Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use'. Together they form a unique fingerprint.

Cite this